186 related articles for article (PubMed ID: 36461603)
21. Identification of cell senescence molecular subtypes in prediction of the prognosis and immunotherapy of hepatitis B virus-related hepatocellular carcinoma.
Yu X; Chen P; Yi W; Ruan W; Xiong X
Front Immunol; 2022; 13():1029872. PubMed ID: 36275676
[TBL] [Abstract][Full Text] [Related]
22. A Differentiation-Related Gene Prognostic Index Contributes to Prognosis and Immunotherapy Evaluation in Patients with Hepatocellular Carcinoma.
Xiao J; Liu T; Liu Z; Xiao C; Du J; Zuo S; Li H; Gu H
Cells; 2022 Jul; 11(15):. PubMed ID: 35892599
[TBL] [Abstract][Full Text] [Related]
23. Immune infiltration and clinical significance analyses of the coagulation-related genes in hepatocellular carcinoma.
He Q; Yang J; Jin Y
Brief Bioinform; 2022 Jul; 23(4):. PubMed ID: 35849048
[TBL] [Abstract][Full Text] [Related]
24. Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma.
He Q; Yang J; Jin Y
Front Immunol; 2022; 13():869993. PubMed ID: 35493518
[TBL] [Abstract][Full Text] [Related]
25. Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes.
Gu X; Guan J; Xu J; Zheng Q; Chen C; Yang Q; Huang C; Wang G; Zhou H; Chen Z; Zhu H
J Transl Med; 2021 Jan; 19(1):26. PubMed ID: 33407546
[TBL] [Abstract][Full Text] [Related]
26. 8DEstablishment and validation of a hypoxia-related signature predicting prognosis in hepatocellular carcinoma.
Cai C; Yang L; Zhou K
BMC Gastroenterol; 2021 Dec; 21(1):463. PubMed ID: 34895169
[TBL] [Abstract][Full Text] [Related]
27. Identification of HM13 as a prognostic indicator and a predictive biomarker for immunotherapy in hepatocellular carcinoma.
Zhang G; Lv X; Yang Q; Liu H
BMC Cancer; 2022 Aug; 22(1):888. PubMed ID: 35964022
[TBL] [Abstract][Full Text] [Related]
28. Estrogen-related genes influence immune cell infiltration and immunotherapy response in Hepatocellular Carcinoma.
Gao B; Wang Y; Li C; Lu S
Front Immunol; 2023; 14():1114717. PubMed ID: 36814910
[TBL] [Abstract][Full Text] [Related]
29. Identification and validation of a fatty acid metabolism-related lncRNA signature as a predictor for prognosis and immunotherapy in patients with liver cancer.
Chen E; Yi J; Jiang J; Zou Z; Mo Y; Ren Q; Lin Z; Lu Y; Zhang J; Liu J
BMC Cancer; 2022 Oct; 22(1):1037. PubMed ID: 36195833
[TBL] [Abstract][Full Text] [Related]
30. A T-cell-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma based on transcriptomics and single-cell sequencing.
Chen X; Peng C; Chen Y; Ding B; Liu S; Song Y; Li Y; Sun B; Yang R
BMC Bioinformatics; 2023 May; 24(1):216. PubMed ID: 37231356
[TBL] [Abstract][Full Text] [Related]
31. Identification of prognostic alternative splicing events related to the immune microenvironment of hepatocellular carcinoma.
Yu S; Cai L; Liu C; Gu R; Cai L; Zhuo L
Mol Med; 2021 Apr; 27(1):36. PubMed ID: 33832428
[TBL] [Abstract][Full Text] [Related]
32. Identification of secretory pathway-related genes based on Random Forest algorithm to predict the prognosis and immunotherapy response of hepatocellular carcinoma.
Wang Z; Shi P; Huang P; Xu C; He Y; Lei W
J Gene Med; 2024 Jan; 26(1):e3593. PubMed ID: 37730948
[TBL] [Abstract][Full Text] [Related]
33. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
34. Characterization of immune features and immunotherapy response in subtypes of hepatocellular carcinoma based on mitophagy.
Wang Y; Peng B; Ning C; He S; Yang H; Mao Y; Sun L
Front Immunol; 2022; 13():966167. PubMed ID: 36304466
[TBL] [Abstract][Full Text] [Related]
35. Establishing a signature based on immunogenic cell death-related gene pairs to predict immunotherapy and survival outcomes of patients with hepatocellular carcinoma.
Ma J; Kuang L; Zhao R
Aging (Albany NY); 2022 Dec; 14(23):9699-9714. PubMed ID: 36516498
[TBL] [Abstract][Full Text] [Related]
36. Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5.
Xu R; Lin L; Zhang B; Wang J; Zhao F; Liu X; Li Y; Li Y
BMC Cancer; 2021 Jun; 21(1):687. PubMed ID: 34112092
[TBL] [Abstract][Full Text] [Related]
37. Construction of a T-cell exhaustion-related gene signature for predicting prognosis and immune response in hepatocellular carcinoma.
Kuang T; Zhang L; Chai D; Chen C; Wang W
Aging (Albany NY); 2023 Jun; 15(12):5751-5774. PubMed ID: 37354485
[TBL] [Abstract][Full Text] [Related]
38. An inflammation-associated ferroptosis signature optimizes the diagnosis, prognosis evaluation and immunotherapy options in hepatocellular carcinoma.
Ruan WY; Zhang L; Lei S; Zeng ZR; Yang YS; Cao WP; Hao QY; Lu M; Tian XB; Peng PL
J Cell Mol Med; 2023 Jul; 27(13):1820-1835. PubMed ID: 37248957
[TBL] [Abstract][Full Text] [Related]
39. Low expression of moonlight gene ALAD is correlated with poor prognosis in hepatocellular carcinoma.
Ye Q; Yang X; Zheng S; Mao X; Shao Y; Xuan Z; Huang P
Gene; 2022 May; 825():146437. PubMed ID: 35318110
[TBL] [Abstract][Full Text] [Related]
40. Four-Pyroptosis Gene-Based Nomogram as a Novel Strategy for Predicting the Effect of Immunotherapy in Hepatocellular Carcinoma.
Li N; Ren SH; Qin YF; Shao B; Qin H; Wang Z; Wang HD; Li GM; Zhu YL; Sun CL; Zhang JY; Shi GG; An XW; Wang H
Biomed Res Int; 2022; 2022():2680110. PubMed ID: 35782053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
